摘要
组蛋白乙酰转移酶(HAT)是表观驱动因子,其催化从乙酰辅酶A向组蛋白和非组蛋白底物的赖氨酸的乙酰基转移,从而通过染色质重塑或直接转录因子活化来诱导转录。组蛋白去乙酰化酶(HDAC)进行逆向反应来抵消HAT活性。诸如细胞周期进程或细胞凋亡的生理过程需要乙酰化和脱乙酰化过程之间相互作用的完全平衡的平衡,以维持或如果需要的话改变整体乙酰化状态。最近已经证实异常HAT活性在各种疾病如前列腺癌,肺癌和结肠癌以及成胶质细胞瘤和神经退行性疾病的进展中起关键作用。最近的研究旨在鉴定HAT调节剂以进一步破译乙酰转移酶相关信号级联的复杂性,并发现药物设计方法的潜在领导。 HDAC已经被小分子广泛地表征和靶向,包括四种FDA批准的HDAC抑制剂;相比之下,HAT尚未成为治疗发展的积极目标。本综述将总结HAT相关疾病的状况以及目前已知和可用的HAT抑制剂的发现,进一步改进和当前应用的情况。
关键词: 组蛋白乙酰转移酶,p300 / CBP,PCAF,GCN5,Tip60,表观遗传学,小分子抑制剂,癌症。
图形摘要
Current Medicinal Chemistry
Title:Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Volume: 24 Issue: 37
关键词: 组蛋白乙酰转移酶,p300 / CBP,PCAF,GCN5,Tip60,表观遗传学,小分子抑制剂,癌症。
摘要: Histone acetyltransferases (HATs) are epigenetic drivers that catalyze the acetyl transfer from acetyl-CoA to lysines of both histone and non-histone substrates and thereby induce transcription either by chromatin remodeling or direct transcription factor activation. Histone deacetylases (HDACs) conduct the reverse reaction to counter HAT activity. Physiological processes such as cell cycle progression or apoptosis require a thoroughly balanced equilibrium of the interplay between acetylation and deacetylation processes to maintain or, if required, alter the global acetylome status. Aberrant HAT activity has recently been demonstrated to play a crucial role in the progression of various diseases such as prostate, lung, and colon cancers as well as glioblastomas and neurodegenerative diseases. Recent investigations have aimed for the identification of HAT modulators to further decipher the complexity of acetyl transferase related signaling cascades and discover potential leads for drug design approaches. HDACs have been extensively characterized and targeted by small molecules, including four FDA-approved HDAC inhibitors; in contrast, HATs have not been active targets for therapeutic development. This review will summarize the status of HAT associated diseases and the arsenal of currently known and available HAT inhibitors with respect to their discovery, further improvements, and current applications.
Export Options
About this article
Cite this article as:
Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease, Current Medicinal Chemistry 2017; 24 (37) . https://dx.doi.org/10.2174/0929867324666170223153115
DOI https://dx.doi.org/10.2174/0929867324666170223153115 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Editorial (Thematic Issue: Endothelium: A Target for Therapeutic Intervention)
Current Vascular Pharmacology An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry The Use of Biomarkers for Bladder Cancer Diagnosis and Surveillance
Mini-Reviews in Medicinal Chemistry Role of PGE2 in Blood Pressure Regulation
Current Hypertension Reviews Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Current Cancer Drug Targets Sonoelastography for Pelvic Metastatic Malignant Pheochromocytoma: A Case Report
Current Medical Imaging Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid
Current Neuropharmacology New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry